Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Opioid breathing risks during sleep under the microscope

NCT ID NCT06854211

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will give a single dose of morphine or a placebo to 26 adults (some healthy, some with obstructive sleep apnea) during a sleep study night. Researchers will measure how much their breathing changes. The goal is to understand why opioids can dangerously slow breathing during sleep, especially in people with sleep apnea.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Morphine
What this could lead to
If successful, this study could help explain why opioids sometimes cause dangerous breathing problems during sleep, potentially leading to safer pain management guidelines.
What could go wrong
This is a very small, early-phase study (26 people) that only looks at breathing changes, not long-term safety or outcomes. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 26 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy controls: Apnea Hypopnea Index (AHI) \< 5 events/hr on in-laboratory PSG within 3 months of enrollment * OSA group: AHI \> 10 events/hr on in-laboratory PSG within 3 months of enrollment; treated or untreated. Exclusion Criteria: * Sleep disordered breathing or respiratory disorders (other than OSA in the OSA group), such as central sleep apnea (\>50% of respiratory events scored as central), chronic hypoventilation/hypoxemia (awake SaO2 \< 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions. * Other sleep disorders: periodic limb movements (periodic limb movement index \> 20/hr), narcolepsy, or parasomnias. * Any unstable major medical condition. * Medications expected to stimulate or depress respiration (including other opioids taken at home, barbiturates, benzodiazepines, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid). * History of allergy to lidocaine or oxymetazoline. * Contraindications for morphine, including: * allergy to morphine or opioids * chronic obstructive pulmonary disease, asthma, or other significant respiratory disorders * kidney or liver dysfunction, as this can affect the metabolism and excretion of morphine, leading to increased risk of toxicity. * women who are pregnant or breastfeeding will be excluded due to potential risks to the fetus or infant. * history of substance abuse, particularly opioid abuse, will be excluded to prevent potential misuse or relapse. * current use of central nervous system depressants. * individuals with gastrointestinal obstruction. Constipation is not an exclusion criterion because morphine is only administered for one night. * recent head injury, brain tumors, or other conditions leading to increased intracranial pressure. * unstable heart disease, particularly those with risk factors for or a history of heart rhythm disorders. * epilepsy or a history of seizures, as morphine can lower the seizure threshold. * severe psychiatric conditions, particularly those with a history of psychosis, as opioids can exacerbate these conditions. * medications that interact with morphine, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), Monoamine oxidase inhibitors (MAOIs), and the atypical antidepressants buproprion and trazodone. * untreated or unstable endocrine disorders like adrenal insufficiency or thyroid dysfunction.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obstructive sleep apnea (OSA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.